Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Beumont

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Lancet (London, England)|June 8, 2014
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trialIra M Jacobson, Gregory J Dore, Graham R Foster, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 12, 2013
Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trialsJames C Sullivan, Sandra De Meyer, Doug J Bartels, et al.
Hepatology (Baltimore, Md.)|August 3, 2013
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR studyMichael W Fried, Maria Buti, Gregory J Dore, et al.
Gut|January 25, 2023
Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infectionHarry L A Janssen, Jinlin Hou, Tarik Asselah, et al.
Hepatology (Baltimore, Md.)|January 30, 2019
JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1Stefan Zeuzem, Stefan Bourgeois, Susan Greenbloom, et al.
Gastroenterology|November 5, 2013
Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trialStefan Zeuzem, Thomas Berg, Edward Gane, et al.
The Lancet. Gastroenterology & Hepatology|July 13, 2023
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trialMan-Fung Yuen, Tarik Asselah, Ira M Jacobson, et al.
Plos One|April 19, 2012
Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trialsTara L Kieffer, Sandra De Meyer, Doug J Bartels, et al.
The European Respiratory Journal|July 17, 2025
Optimal dosing and duration of linezolid for the treatment of multidrug-resistant and rifampicin-resistant tuberculosis: an individual patient data meta-analysisNakwon Kwak, Joong-Yub Kim, Areum Han, et al.
Lancet (London, England)|August 1, 2014
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised studyEric Lawitz, Mark S Sulkowski, Reem Ghalib, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Lancet (London, England)|June 8, 2014
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trialIra M Jacobson, Gregory J Dore, Graham R Foster, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 12, 2013
Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trialsJames C Sullivan, Sandra De Meyer, Doug J Bartels, et al.
Hepatology (Baltimore, Md.)|August 3, 2013
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR studyMichael W Fried, Maria Buti, Gregory J Dore, et al.
Gut|January 25, 2023
Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infectionHarry L A Janssen, Jinlin Hou, Tarik Asselah, et al.
Hepatology (Baltimore, Md.)|January 30, 2019
JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1Stefan Zeuzem, Stefan Bourgeois, Susan Greenbloom, et al.
Gastroenterology|November 5, 2013
Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trialStefan Zeuzem, Thomas Berg, Edward Gane, et al.
The Lancet. Gastroenterology & Hepatology|July 13, 2023
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trialMan-Fung Yuen, Tarik Asselah, Ira M Jacobson, et al.
Plos One|April 19, 2012
Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trialsTara L Kieffer, Sandra De Meyer, Doug J Bartels, et al.
The European Respiratory Journal|July 17, 2025
Optimal dosing and duration of linezolid for the treatment of multidrug-resistant and rifampicin-resistant tuberculosis: an individual patient data meta-analysisNakwon Kwak, Joong-Yub Kim, Areum Han, et al.
Lancet (London, England)|August 1, 2014
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised studyEric Lawitz, Mark S Sulkowski, Reem Ghalib, et al.
Pageof 5